Gastrointestinal stromal tumors (GIST)

Gastroenterologie Clinique et Biologique

Volumn 30, Issue HS2, 2006, Pages

  Landi, Bruno ^a   Bouche, Olivier ^b   Blay, Jean Yves ^c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; REVIEW; TREATMENT OUTCOME;

FRANCE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; PRACTICE GUIDELINES; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 33846046531     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73595-3     Document Type: Review

References (14)

1. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors *Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
2. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-6.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical and molecular features and differential diagnosis. Virchows Arch 2001;438:1-12.
4. Fletcher CDM, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
5. Landi B, Lecomte T, Berger A, Cellier C Traitement des tumeurs stromales digestives. Gastroenterol Clin Biol 2004;28:893-901.
6. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 2003;39:2012-20.
7. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol. 2004;85:704-12.
8. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
9. Plaat BE, Hollema H., Molenaar W.M., et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
10. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
11. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al.Efficacy and safety of imatinib in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
12. Verweij J, Casali PG, J Zalcberg J, Le Cesne A, Reichard P, Blay JY, et al.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.. Lancet 2004;364:1127-34.
13. RS Benjamin, C Rankin, C Fletcher, C Blanke, M Von Mehren, R Maki, et al. Phase III doserandomized study of imatinib mesylate (Glivec, STI571) for GIST : Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:a3271(abstract).
14. Savage DG, Antman KH. Imatinib- a new oral targeted therapy. N Engl J Med. 2002 Feb 28;346(9):683-93